Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies

Neuromuscular Disorders

Volumn 9, Issue 4, 1999, Pages 239-246

  De Bleecker, Jan L ^a   Meire, Veronique I ^a   Declercq, Wim ^a,b   Van Aken, Elisabeth H ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Immunology; Inflammatory myopathies; Pathology; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; INCLUSION BODY MYOSITIS; INFLAMMATORY INFILTRATE; MACROPHAGE; MUSCLE BIOPSY; MYOPATHY; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD; DERMATOMYOSITIS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; MUSCLE, SKELETAL; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0033023483     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(98)00126-6     Document Type: Article

References (48)

1. De Bleecker J.L., Engel A.G. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol. 53:1994;369-376.
2. Tews D.S., Goebel H.H. Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol. 59:1995;185-194.
3. De Bleecker J.L., Engel A.G., Butcher E.C. Peripheral lymphoid tissue-like adhesion molecule expression in nodular infiltrates in inflammatory myopathies. Neuromusc Disord. 6:1996;255-260.
4. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 16:1984;193-208.
5. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. V. Identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol. 23:1988;493-499.
6. Dalakas M.C. Polymyositis, dermatomyositis, and inclusion body myositis. N Engl J Med. 325:1991;1487-1498.
7. Griggs R.C., Askanas V., DiMauro S.et al. Inclusion body myositis and myopathies. Ann Neurol. 38:1995;705-713.
8. Emslie-Smith A.M., Engel A.G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 27:1990;343-356.
9. De Bleecker J.L., Engel A.G. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am J Pathol. 146:1995;1178-1187.
10. Lichtman A.H., Ding H., Henault L.et al. CD45RA-RO+ (memory) but not CD45RA+RO-(naive) T cells roll efficiently on E- and P-selectin and vascular cell adhesion molecule-1 under flow. J Immunol. 158:1997;3640-3650.
11. Michaelis D., Goebels N., Hohlfeld R. Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. Am J Pathol. 143:1993;1142-1149.
12. Emslie-Smith A.M., Arahata K., Engel A.G. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 20:1989;224-231.
13. Isenberg D.A., Rowe D.J., Shearer M.et al. Localization of interferon and interleukin-2 in polymyositis and muscular dystrophy. Clin Exp Immunol. 63:1986;450-458.
14. Illa I., Gallardo E., Gimeno R., Serrano C., Ferrer I., Juárez C. Signal transducer and activator of transcription 1 in human muscle. Implications in inflammatory myopathies. Am J Pathol. 151:1997;81-88.
15. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 285:1991;199-212.
16. Vandenabeele P., Declercq W., Vercammen D.et al. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med. 176:1992;1015-1024.
17. Brockhaus M., Schoenfeld H., Schlaeger E., Hunziker W., Lesslauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA. 87:1990;3127-3131.
18. Erikstein B.K., Smeland E.B., Blomhoff H.K.et al. Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes. Eur J Immunol. 21:1991;1033-1037.
19. Van Ostade X., Vandenabeele P., Everaerdt B.et al. Human TNF mutants with selective activity on the p55 receptor. Nature. 316:1993;266-269.
20. Heller R.A., Song K., Fan N., Chang D.J. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell. 70:1992;47-56.
21. Barbara JAJ, Smith WB, Gamble JR, et al. Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-α mutants. EMBO J 1994;13:843-850.
22. Slowik MR, De Luca LG, Fiers W, Pober JS. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 1993;143:1724-1730.
23. Mackay F., Loetscher H., Stueber D., Gehr G., Lesslauer W. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med. 177:1993;1277-1286.
24. Vandenabeele P., Declercq W., Vanhaesebroeck B., Grooten J., Fiers W. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol. 154:1995;2904-2913.
25. Loetscher H., Stueber D., Banner D., Mackay F., Lesslauer W. Human tumor necrosis factor alpha mutants with exclusive specificity for the 55-kDa TNF receptors. J Biol Chem. 268:1993;2635-3642.
26. Neumann B., Machleidt T., Lifka A.et al. Crucial role of 55-kilodalton TNF receptor in TNF-induced adhesion molecule expression and leucocyte organ infiltration. J Immunol. 156:1996;1587-1593.
27. Tartaglia L.A., Pennica D., Goeddel D.V. Ligand passing: the 75-kDA tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDA TNF receptor. J Biol Chem. 68:1993;18542-18548.
28. Tartaglia L.A., Goeddel D.V., Reynolds C. Stimulation of human T-cell proliferation by specific activation of the 75-kDA tumor necrosis factor receptor. J Immunol. 151:1993;4637-4641.
29. De Bleecker J.L., Engel A.G., Winkelmann J.C. Localization of dystrophin and β-spectrin in vacuolar myopathies. Am J Pathol. 143:1993;1200-1208.
30. Cashman N.R., Covault J., Wollman R.L., Sanes J.R. Neural cell adhesion molecule in normal, denervated, and myopathic human muscle. Ann Neurol. 21:1987;481-489.
31. Lundberg I., Brengman J.M., Engel A.G. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 63:1995;9-16.
32. Andreetta F., Bernasconi P., Torchiana E., Baggi F., Cornelio F., Mantegazza R. T-cell infiltration in polymyositis is characterized by coexpression of cytotoxic and T-cell-activating cytokine transcripts. Ann NY Acad Sci. 756:1995;418-420.
33. Tews D.S., Goebel H.H. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol. 55:1996;342-347.
34. Lindberg C., Oldfors A., Tarkowski A. Local T-cell proliferation and differentiation in inflammatory myopathies. Scand J Immunol. 41:1995;421-426.
35. Gherardi R.K., Florea-Strat A., Fromont G., Poron F., Sabourin J., Authier J. Cytokine expression in the muscle of HIV-infected patients: evidence for Interleukin-1alpha accumulation in mitochondria of AZT fibers. Ann Neurol. 36:1994;752-758.
36. Hickey M.J., Reinhardt P.H., Ostrovsky L.et al. Tumor necrosis factor-α induces leukocyte recruitment by different mechanisms in vivo and in vitro. J Immunol. 158:1997;3391-3400.
37. Porteu F., Hieblot C. Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J Biol Chem. 269:1994;2834.
38. Pinckard K.J., Sheehan K.C.F., Arthur C.D., Schreiber R.D. Constitutive shedding of both p55 and p75 murine TNF receptors in vivo. J Immunol. 158:1997;3869-3873.
39. Akopov S.E., Simonian N.A., Grigorian G.S. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke. 27:1996;1739-1743.
40. Beutler B., Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature. 320:1986;584-588.
41. Emslie-Smith A.M., Arahata K., Engel A.G. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 20:1989;224-231.
42. Karpati G., Pouliot Y., Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol. 23:1988;64-72.
43. Yamada Y., Kirillova I., Peschon J.J., Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA. 94:1997;1441-1446.
44. Santee S.M., Owen-Schaub L.B. Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J Biol Chem. 271:1996;21151-21159.
45. Mantegazza R., Gebbia M., Mora M.et al. Major histocompatibility complex class II molecule expression on muscle cells is regulated by differentiation: implications for the immunopathogenesis of muscle autoimmune diseases. J Neuroimmunol. 68:1996;53-60.
46. Miller S.C., Ito H., Blau H.M., Torti F.M. Tumor necrosis factor inhibits human myogenesis in vitro. Mol Cell Biol. 8:1988;2295-2301.
47. Boldin M.P., Mett I.L., Varfolomeev E.E.et al. Self-association of the 'death domains' of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem. 270:1995;387-391.
48. Kilgore K.S., Schmid E., Shanley T.P.et al. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemo-attractant protein-1 through nuclear factor-kB activation. Am J Pathol. 150:1997;2019-2031.